Trexquant Investment LP reduced its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 33.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,563 shares of the company's stock after selling 28,732 shares during the period. Trexquant Investment LP owned approximately 0.06% of ARS Pharmaceuticals worth $597,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new position in ARS Pharmaceuticals in the 4th quarter valued at $73,000. Compass Capital Corp MA ADV purchased a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth $106,000. Teacher Retirement System of Texas bought a new stake in ARS Pharmaceuticals during the fourth quarter valued at $122,000. Amica Mutual Insurance Co. purchased a new position in ARS Pharmaceuticals during the fourth quarter worth about $151,000. Finally, SBI Securities Co. Ltd. bought a new position in ARS Pharmaceuticals in the 4th quarter worth about $175,000. 68.16% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other news, Director Laura Shawver sold 50,000 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $12.31, for a total value of $615,500.00. Following the transaction, the director now owns 210,346 shares in the company, valued at approximately $2,589,359.26. This trade represents a 19.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Karas sold 10,000 shares of the company's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the sale, the insider now owns 7,696 shares of the company's stock, valued at $107,744. This represents a 56.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 159,602 shares of company stock valued at $1,926,541 in the last ninety days. Company insiders own 40.10% of the company's stock.
ARS Pharmaceuticals Stock Performance
NASDAQ:SPRY traded up $0.52 during trading hours on Tuesday, reaching $14.99. The company's stock had a trading volume of 1,258,179 shares, compared to its average volume of 1,142,474. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -29.39 and a beta of 0.86. The firm has a 50-day simple moving average of $12.08 and a 200-day simple moving average of $13.04. ARS Pharmaceuticals, Inc. has a 1 year low of $7.55 and a 1 year high of $18.51.
ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.56. The company had revenue of $86.58 million for the quarter, compared to the consensus estimate of $15.46 million. Equities analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research analysts have recently commented on SPRY shares. William Blair reissued an "outperform" rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Leerink Partners increased their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They set an "outperform" rating and a $40.00 price objective on the stock. Raymond James upped their target price on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a research report on Tuesday, January 14th. Finally, Scotiabank began coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $31.00.
Check Out Our Latest Analysis on ARS Pharmaceuticals
ARS Pharmaceuticals Profile
(
Free Report)
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
See Also
Before you consider ARS Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.
While ARS Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
